The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

The heart tissue showed upregulation of molecular pathways that help recruit and retain immune cells involved in inflammation ...

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can dramatically improve outcomes for many cancers. But for about 70% of patients, these ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

Intravital microscopy (IVM) enables live imaging of animals at single-cell level, offering essential insights into ... n represents independent positions in 6 biological replicates. Two-tailed ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...